ArticleiScience2026
Patient-derived organoids support radiotherapy response and recurrence risk prediction in esophageal squamous cancer.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting individual responses to radiotherapy remains a major challenge in esophageal cancer. This study evaluated an cancer organoid-based diagnosis and reactivity prediction (CODRP) approach to estimate pathological response and recurrence risk after neoadjuvant chemoradiotherapy (NCRT) in esophageal squamous cell carcinoma. Organoids were established from endoscopic biopsy specimens and irradiated with doses of 2, 4, or 8 Gy. Growth inhibition-based area under the curve (GI-AUC) and cell growth rates were quantified and integrated with the clinical cancer stage to generate the CODRP index. Compared with single-parameter models, the CODRP showed improved apparent predictive performance for pathological response prediction in this feasibility cohort (sensitivity, 87.5%; specificity, 100%). Recurrence-free survival was significantly higher in the CODRP-classified radiation-sensitive group (71.43%) than in the radiation-resistant group (10%) (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.